A Novel Live-Attenuated Vaccine Candidate for Mayaro Fever

被引：48
|
作者：
Weise, William J. [1 ]
Hermance, Meghan E.
Forrester, Naomi
Adams, A. Paige
Langsjoen, Rose
Gorchakov, Rodion
Wang, Eryu
Alcorn, Maria D. H.
Tsetsarkin, Konstantin
Weaver, Scott C.
机构：
[1] Univ Texas Med Branch, Inst Human Infect & Immun, Ctr Trop Dis, Galveston, TX 77555 USA
来源：
PLOS NEGLECTED TROPICAL DISEASES | 2014年 / 8卷 / 08期
基金：
美国国家卫生研究院;
关键词：
EQUINE ENCEPHALITIS-VIRUS; CHIKUNGUNYA VIRUS; CYNOMOLGUS MACAQUES; ENCEPHALOMYELITIS VIRUS; NONHUMAN-PRIMATES; AMAZON BASIN; INFECTION; DISEASE; STRAIN; ALPHAVIRUSES;
D O I：
10.1371/journal.pntd.0002969
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Mayaro virus (MAYV) is an emerging, mosquito-borne alphavirus that causes a dengue-like illness in many regions of South America, and which has the potential to urbanize. Because no specific treatment or vaccine is available for MAYV infection, we capitalized on an IRES-based approach to develop a live-attenuated MAYV vaccine candidate. Testing in infant, immunocompetent as well as interferon receptor-deficient mice demonstrated a high degree of attenuation, strong induction of neutralizing antibodies, and efficacy against lethal challenge. This vaccine strain was also unable to infect mosquito cells, a major safety feature for a live vaccine derived from a mosquito-borne virus. Further preclinical development of this vaccine candidate is warranted to protect against this important emerging disease.
引用
收藏
页数：9
相关论文
共 50 条
  • [1] In-depth characterization of a novel live-attenuated Mayaro virus vaccine candidate using an immunocompetent mouse model of Mayaro disease
    Mânlio Tasso de Oliveira Mota
    Vivian Vasconcelos Costa
    Michelle Amantéa Sugimoto
    Georgia de Freitas Guimarães
    Celso Martins Queiroz-Junior
    Thaiane Pinto Moreira
    Carla Daiane de Sousa
    Franciele Martins Santos
    Victoria Fulgêncio Queiroz
    Ingredy Passos
    Josy Hubner
    Danielle Gloria Souza
    Scott C. Weaver
    Mauro Martins Teixeira
    Maurício Lacerda Nogueira
    Scientific Reports, 10
  • [2] In-depth characterization of a novel live-attenuated Mayaro virus vaccine candidate using an immunocompetent mouse model of Mayaro disease
    de Oliveira Mota, Manlio Tasso
    Costa, Vivian Vasconcelos
    Sugimoto, Michelle Amantea
    Guimaraes, Georgia de Freitas
    Queiroz-Junior, Celso Martins
    Moreira, Thaiane Pinto
    de Sousa, Carla Daiane
    Santos, Franciele Martins
    Queiroz, Victoria Fulgencio
    Passos, Ingredy
    Hubner, Josy
    Souza, Danielle Gloria
    Weaver, Scott C.
    Teixeira, Mauro Martins
    Nogueira, Mauricio Lacerda
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [3] Phenotypic and genetic characterization of a next generation live-attenuated yellow fever vaccine candidate
    Esson, Raphael
    De Sousa, Emanuel Rodrigues
    Benair, Loic
    Devard, Nicolas
    Soulet, Damien
    Gillet, Audrey
    Bassard, Isabelle
    Falque, Stephanie
    Chareyre, Audrey
    Marmin, Morgane
    Girerd-Chambaz, Yves
    Logvinoff, Carine
    Sanchez, Martha Erika Navarro
    VACCINE, 2022, 40 (38) : 5641 - 5650
  • [4] Live-attenuated varicella vaccine
    Gershon, AA
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2001, 15 (01) : 65 - +
  • [5] Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate
    Ikegami, Tetsuro
    EXPERT REVIEW OF VACCINES, 2017, 16 (06) : 601 - 611
  • [6] Live-attenuated chikungunya virus vaccine
    Ng, Lisa F. P.
    Renia, Laurent
    CELL, 2024, 187 (04)
  • [7] Development of a novel equine influenza virus live-attenuated vaccine
    Rodriguez, Laura
    Reedy, Stephanie
    Nogales, Aitor
    Murcia, Pablo R.
    Chambers, Thomas M.
    Martinez-Sobrido, Luis
    VIROLOGY, 2018, 516 : 76 - 85
  • [8] An effective live-attenuated Zika vaccine candidate with a modified 5′ untranslated region
    Nazneen, Farzana
    Thompson, E. Ashley
    Blackwell, Claire
    Bai, Jonathan S.
    Huang, Faqing
    Bai, Fengwei
    NPJ VACCINES, 2023, 8 (01)
  • [9] Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate
    Mason, PW
    Piccone, ME
    McKenna, TSC
    Chinsangaram, J
    Grubman, MJ
    VIROLOGY, 1997, 227 (01) : 96 - 102
  • [10] An effective live-attenuated Zika vaccine candidate with a modified 5′ untranslated region
    Farzana Nazneen
    E. Ashley Thompson
    Claire Blackwell
    Jonathan S. Bai
    Faqing Huang
    Fengwei Bai
    npj Vaccines, 8
12345